## PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Sunil Chada et al

Serial No.: 10/017.472

Filed: December 7, 2001

For: METHOD OF TREATMENT INVOLVING HUMAN MDA-7 Group Art Unit: 1633

Examiner: Li, Qian Janice

Atty. Dkt. No.: INGN:097US

Confirmation No.: 5209

CERTIFICATE OF ELECTRONIC TRANSMISSION 57 C.F.R. § 1.8.

I hereby certify that this correspondence is being electronically filed with the United States Patient and Trademark Office via EESAMeho at the date below:

March 2, 2007

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

## MS AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

A fee as set forth in 37 C.F.R. § 1.17(p) in the amount of \$180.00 is enclosed. If an appropriate payment has not been enclosed, or if it is insufficient, the Commissioner is authorized to deduct the appropriate fee from Pulbright & Jaworski Account No.: 50-1212/INGN:097US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

Travis Wohlers Reg. No. 57,423 Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 474-5201

Date: March 2, 2007

							Page 1 of 2		
Form PTO-1449 (modified)				Atty. Docket No.: Serial No.:					
				INGN:097US	INGN:097US 10/017,472				
List of P	atents an	d Publications for	Applicant's	Applicant:					
				Sunil Chada et al.					
INF	ORMATIC	ON DISCLOSURE ST	ATEMENT						
				Filing Date: Group:					
		everal sheets if necessar	.,	December 7, 2001	1	533			
				atent Documents	Other Art				
See Page 1 S				ce Page I	I See Page 1-2				
			U.S. Pate	nt Documents					
Exam.	Ref.	Document	Date	Name	Class		Filing Date		
Init.	Des.	Number				Class	of App.		
		F	oreign Pa	tent Document	s				
Exam.	Ref.	Document	Date	Country		Langu	age		
Init.	Des.	Number							
	Other	Art (Includin	g Author,	Title, Date Per	tinent l	Pages,	Etc.)		
Exam.	Ref.	Citation							
Init.	Des.								
	C262	Bocangel et al., "Combinatorial synergy induced by adenoviral-mediated mda-7 and Herceptin							
					or Gene Therapy, 1-11, 2006.				
	C263	Chada et al., "mda-7 gene transfer sensitizes breast carcinoma cells to chemotherapy, biological							
		therapies and radiotherapy: correlation with expression of bcl-2 family members," Cancer Gene							
		Therapy, 1-13, 20	05.						
	C264	Emdad et al., "Ionizing Radiation Enhances Adenoviral Vector Expressing mds-7/IL-24-							
		mediated Apoptosis in Human Ovarian Cancer," J. Cell Physiol., 208:298-306, 2006.							
	C265	Inoue et al., "MDA-7/IL-24-Based Cancer Gene Therapy: Translation from the Laboratory to the Clinic," Current Gene Therapy, 6:73-91, 2006.							
	C266	Kawabe et al., "A	lenovirus-Medi	ated mda-7 Gene Expre	ssion Radio	sensitizes N	on-Small Cell		
		Lung Cancer Cells	via TP53-Indep	endent Mechanisms,"	Molecular 1	herapy, 6:63	37-644, 2002.		
	C267	McKenzie et al., "Combination therapy of Ad-mda7 and trastuzumab increases cell death in							
		Her-2/neu-overexpressing breast cancer cells," Surgery, 136:437-442, 2004.							
	C268	Nishikawa et al., "Adenoviral-mediated mda-7 expression suppresses DNA repair capacity and							
		radiosensitizes non-small-cell lung cancer cells," Oncogene, 23:7125-7131, 2004.							
	C269	Nishikawa et al., "Adenovirus-Mediated mda-7 (IL24) Gene Therapy Suppresses Angiogenesis and Sangiting NSCI C Yeaport II Turney to Parliction "Med. Therapy 9-218-229, 2004							

25751368.1

EXAMINER: DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETEINER OR NOT CITATION IS IN CONFIDERANCE WITH MPEPS 09, DRAW LINE THROUGH CITATION IS NOT ON CONFIDERANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NICKT COMMUNICATION TO APPLICANT.

Other Art

See Page 1-2

Form PTO-1449 (modified)	Atty. Docket No.:	Serial No.:
	INGN:097US	10/017,472
List of Patents and Publications for Applicant's	Applicant:	
	Sunil Chada et al.	
INFORMATION DISCLOSURE STATEMENT		
	Filing Date:	Group:
(Use several sheets if necessary)	December 7, 2001	1633

Foreign Patent Documents See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)				
Exam. Init.	Ref. Des.	Citation		
	C270	Su et al., "Ionizing radiation enhances therapeutic activity of mda-7/IL-24: overcoming radiation- and mda-7/IL-24-resistance in prostrate cancer cells overexpressing the antiapoptotic portains below on the prostrate cancer cells overexpressing the antiapoptotic portains below on the prostrate cancer cells overexpressing the antiapoptotic portains below on the prostrate cancer cells overexpressing the antiapoptotic portains below on the prostrate cancer cells overexpressing the antiapoptotic portains below on the prostrate cancer cells overexpressing the antiapoptotic portains below on the prostrate cancer cells overexpressing the antiapoptotic prostrate cancer cells overexpressing the prostrate cancer cells overexpressing the antiapoptotic prostrate cancer cells overexpressing the cancer cells overexpressing t		

25751368.1

U.S. Patent Documents

See Page 1

DATE CONSIDERED: EXAMINER:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609, DIAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT